Not FDA-approved3Evidence: Limited human dataBrain, nerves and sleep

Selank1,3

Also called Selank acetate3

Key takeaway

Selank is a synthetic seven-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro), recorded in FDA’s substance registry and also known as TP-7.1,3 The only human study found in this review is a 2015 Russian study of 70 patients with anxiety disorders, in which selank was added to the tranquilizer phenazepam; its design and results can be checked only from its abstract.6 FDA lists selank acetate among compounding nominations that were withdrawn after FDA identified possible safety risks, and states that it lacks important information on its safety in people.3 No FDA approval is reported in the sources reviewed here, and selank is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.3,5

Selank at a glance

What it isA synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, according to FDA’s substance registry.1
FDA statusNo FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page lists selank acetate among withdrawn nominations with possible safety risks.3
Human evidenceOne small Russian clinical study of selank added to phenazepam, reported in a Russian journal. FDA states that it lacks important information on selank’s safety in people.3,6
Evidence strengthLimited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned

What is selank?

Selank is a synthetic peptide of seven amino acids: threonine, lysine, proline, arginine, proline, glycine and proline. FDA’s substance registry records it as selank and TP 7.1

FDA’s compounding safety-risk page refers to it as selank acetate (TP-7).3

How is selank thought to work?

The authors of a 2017 rat study describe selank as an anxiety-reducing peptide whose action may resemble that of benzodiazepine drugs.2

That proposed mechanism comes from animal research; the FDA sources reviewed here do not describe how selank acts in people.2,3

What do human studies show?

A 2015 Russian study compared the tranquilizer phenazepam alone in 30 patients with phenazepam plus selank in 40 patients with anxiety-phobic, hypochondriac and somatoform disorders.6

The authors report that phenazepam took effect sooner on a depression and anxiety rating scale when selank was added, that side effects of phenazepam such as poor attention and memory, sedation and fatigue were reduced, and that quality of life improved.6

The study is small, tested selank only alongside phenazepam, and is reported in Russian; its abstract does not say how patients were assigned or whether they or the assessors knew which treatment they had.6

FDA states that it lacks important information regarding any safety issues raised by selank acetate given to humans.3

What the evidence base contains

  • Small, short, or incompletely reported human study A 2015 Russian study of 70 patients with anxiety disorders comparing phenazepam alone (30 patients) with phenazepam plus selank (40 patients). The abstract does not describe how patients were assigned to the groups.6
  • Animal or laboratory research A 2017 rat study reporting that selank reduced anxiety-like behaviour in a maze test, alone and combined with diazepam, under chronic mild stress.2

Evidence-strength label: Limited human data. How this label is assigned

Is selank FDA-approved?

None of the sources reviewed here reports an approval of selank by FDA.1,3

FDA’s compounding safety-risk page, current as of April 22, 2026, lists selank acetate among bulk drug substances that were in category 2 before their nominations were withdrawn, citing possible immune reactions from aggregation and impurities.3

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Selank is not among them.4,5

Timeline

  1. A Russian clinical study of selank added to phenazepam in anxiety disorders is published.6
  2. A rat study of selank under chronic mild stress is published.2
  3. FDA’s compounding safety-risk page, as last updated, lists selank acetate among withdrawn nominations with possible safety risks.3

What is still unknown?

Whether selank on its own is effective for anxiety: the human study reviewed here added it to phenazepam, and its methods can be checked only from the abstract.6

Whether it is safe in people: FDA states that it lacks important safety information.3

Whether effects seen in rats would carry over to people.2

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Selank: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Selank are a bounded selection, not every registration or paper about Selank. For the years before Selank was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Selank as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Selank in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

No FDA approval reported; FDA lists safety concerns from a withdrawn compounding nomination. The only human study found is a small 2015 Russian study of selank added to phenazepam in anxiety disorders, checkable only from its abstract; the other published work cited here is in rats. No FDA approval is reported, and selank is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Selank?

No FDA approval reported; FDA lists safety concerns from a withdrawn compounding nomination. The only human study found is a small 2015 Russian study of selank added to phenazepam in anxiety disorders, checkable only from its abstract; the other published work cited here is in rats. No FDA approval is reported, and selank is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
1
Source years
4
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 16, 2026

    A new property of the synthetic anxiolytic Selank and its derivatives.↗Source date October 16, 2026
  2. Literature metadata · added November 16, 2026

    Antiviral properties of structural fragments of the peptide Selank.↗Source date October 16, 2026
  3. Literature metadata · added November 16, 2026

    Use of Selank to correct measures of integrative brain activity and biogenic amine levels in adult rats resulting from antenatal hypoxia.↗Source date October 11, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected clinical trial records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Selank?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

13Selected dated records
19Connected citations
4Populated source years2018–2026
1/4Record lanes present

Registered human studies

Trial composition

0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.

PubMed bibliography

Publication composition

13 of 13 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 13Research Support, Non-U.S. Gov't 5Randomized Controlled Trial 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
13

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 13 dated records

Research hub

Explore the Selank evidence record

Open all 13 records →
13Dated records
1Evidence type
13Cited public sources
4Source years

Change ledger

Recently changed for Selank

Open all 14 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Profile updated

Selank profile

We added a 2015 Russian clinical study of selank added to phenazepam in patients with anxiety disorders. Earlier versions said no human study was cited among the sources reviewed.

PeptideScanner change date
November 16, 2026
Evidence lane
Profile
Record added

A new property of the synthetic anxiolytic Selank and its derivatives.

PubMed lists PMID 15508574 in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2004 Jul-Aug (source-text precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
October 16, 2026
Evidence lane
Literature metadata
Record added

Selank and its metabolites maintain homeostasis in the gastric mucosa.

PubMed lists PMID 18019011 in Bulletin of experimental biology and medicine as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-01 (month precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
August 13, 2019
Evidence lane
Literature metadata

Official-source collections

Source records for Selank

Open the full research atlas →

Evidence types

Coverage by source year

Selected records span December 17, 2018 to October 16, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,3
  • U.S. Department of Health and Human Services4
Dated updates connected to this profile · 13

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    A new property of the synthetic anxiolytic Selank and its derivatives.↗

    PubMed lists PMID 15508574 in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2004 Jul-Aug (source-text precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Antiviral properties of structural fragments of the peptide Selank.↗

    PubMed lists PMID 20506839 in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010 Mar-Apr (source-text precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Use of Selank to correct measures of integrative brain activity and biogenic amine levels in adult rats resulting from antenatal hypoxia.↗

    PubMed lists PMID 18197389 in Neuroscience and behavioral physiology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-02 (month precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    The influence of Selank on the parameters of the hemostasis system, lipid profile, and blood sugar level in the course of experimental metabolic syndrome.↗

    PubMed lists PMID 25371249 in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections as Journal Article, with publication-date metadata of 2014-11-05 (day precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells.↗

    PubMed lists PMID 28293190 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2017-02-28 (day precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    State of Colon Microbiota in Rats during Chronic Restraint Stress and Selank Treatment.↗

    PubMed lists PMID 31236882 in Bulletin of experimental biology and medicine as Journal Article, with publication-date metadata of 2019-06-24 (day precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    [Transcriptome alteration in hippocampus under the treatment of tuftsin analog Selank].↗

    PubMed lists PMID 24450168 in Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova as Journal Article, with publication-date metadata of 2013 May-Jun (source-text precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Selank and its metabolites maintain homeostasis in the gastric mucosa.↗

    PubMed lists PMID 18019011 in Bulletin of experimental biology and medicine as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-01 (month precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity.↗

    PubMed lists PMID 30255741 in Protein and peptide letters as Journal Article, with publication-date metadata of 2018 (year precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    [Antiviral activity of immunomodulator Selank in experimental influenza infection].↗

    PubMed lists PMID 19882898 in Voprosy virusologii as Journal Article, with publication-date metadata of 2009 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    [Experimental optimization of learning and memory processes by selank].↗

    PubMed lists PMID 20919548 in Eksperimental'naia i klinicheskaia farmakologiia as Journal Article, with publication-date metadata of 2010-08 (month precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank.↗

    PubMed lists PMID 21609736 in Regulatory peptides as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2011-05-24 (day precision). PeptideScanner associated the retained record with the identity slug selank. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Selank substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  2. 2
    Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats (2017) · PMID 28280289 ↗

    Behavioural Neurology · Official source · Source checked November 15, 2026

  3. 3
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    Optimization of the treatment of anxiety disorders with selank (2015, in Russian) · PMID 26356395 ↗

    Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · Official source · Source checked November 16, 2026